Immix Biopharma Inc (NASDAQ: IMMX)’s stock price has dropped by -18.85 in relation to previous closing price of 2.60. Nevertheless, the company has seen a gain of 7.11% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.
Is It Worth Investing in Immix Biopharma Inc (NASDAQ: IMMX) Right Now?
The stock has a 36-month beta value of 0.30. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMMX is 16.60M, and at present, short sellers hold a 1.29% of that float. On June 04, 2025, the average trading volume of IMMX was 153.93K shares.
IMMX’s Market Performance
IMMX stock saw an increase of 7.11% in the past week, with a monthly gain of 0.72% and a quarterly increase of 29.45%. The volatility ratio for the week is 15.83%, and the volatility levels for the last 30 days are 8.88% for Immix Biopharma Inc (IMMX). The simple moving average for the past 20 days is -0.55% for IMMX’s stock, with a 12.38% simple moving average for the past 200 days.
IMMX Trading at 11.90% from the 50-Day Moving Average
After a stumble in the market that brought IMMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.14% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMMX starting from Hsu Jason, who purchase 40,000 shares at the price of $2.19 back on Dec 23 ’24. After this action, Hsu Jason now owns 893,000 shares of Immix Biopharma Inc, valued at $87,680 using the latest closing price.
Hsu Jason, the Director of Immix Biopharma Inc, purchase 7,700 shares at $2.17 during a trade that took place back on Dec 20 ’24, which means that Hsu Jason is holding 853,000 shares at $16,678 based on the most recent closing price.
Stock Fundamentals for IMMX
The total capital return value is set at -2.06. Equity return is now at value -111.42, with -77.05 for asset returns.
Based on Immix Biopharma Inc (IMMX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -11.76.
Currently, EBITDA for the company is -21.54 million with net debt to EBITDA at 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
To sum up, Immix Biopharma Inc (IMMX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
